246 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author윤채옥-
dc.date.accessioned2017-10-25T00:45:20Z-
dc.date.available2017-10-25T00:45:20Z-
dc.date.issued2015-12-
dc.identifier.citationMATHEMATICAL BIOSCIENCES AND ENGINEERING, v. 12, NO 6, Page. 1237-1256en_US
dc.identifier.issn1547-1063-
dc.identifier.issn1551-0018-
dc.identifier.urihttp://www.aimsciences.org/journals/displayArticlesnew.jsp?paperID=11563-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/30252-
dc.description.abstractOncolytic viruses (OVs) are used to treat cancer, as they selectively replicate inside of and lyse tumor cells. The efficacy of this process is limited and new OVs are being designed to mediate tumor cell release of cytokines and co-stimulatory molecules, which attract cytotoxic T cells to target tumor cells, thus increasing the tumor-killing effects of OVs. To further promote treatment efficacy, OVs can be combined with other treatments, such as was done by Huang et al., who showed that combining OV injections with dendritic cell (DC) injections was a more effective treatment than either treatment alone. To further investigate this combination, we built a mathematical model consisting of a system of ordinary differential equations and fit the model to the hierarchical data provided from Huang et al. We used the model to determine the effect of varying doses of OV and DC injections and to test alternative treatment strategies. We found that the DC dose given in Huang et al. was near a bifurcation point and that a slightly larger dose could cause complete eradication of the tumor. Further, the model results suggest that it is more effective to treat a tumor with immunostimulatory oncolytic viruses first and then follow-up with a sequence of DCs than to alternate OV and DC injections. This protocol, which was not considered in the experiments of Huang et al., allows the infection to initially thrive before the immune response is enhanced. Taken together, our work shows how the ordering, temporal spacing, and dosage of OV and DC can be chosen to maximize efficacy and to potentially eliminate tumors altogether.en_US
dc.description.sponsorshipThe authors received support from the Australian Research Council (DE120101113); the University of Richmond Faculty Research Committee; the Weill Cornell Medical Student Executive Council and Office of Academic Affairs; and the National Research Foundation of Korea (2010-0029220 & 2013M3A9D3045-879).en_US
dc.language.isoenen_US
dc.publisherAMER INST MATHEMATICAL SCIENCESen_US
dc.subjectOncolytic virotherapyen_US
dc.subjectadenovirusen_US
dc.subjectcytokinesen_US
dc.subjectco-stimulatory moleculesen_US
dc.subjectmathematical modelen_US
dc.subjectordinary differential equations modelen_US
dc.titleTREATMENT STRATEGIES FOR COMBINING IMMUNOSTIMULATORY ONCOLYTIC VIRUS THERAPEUTICS WITH DENDRITIC CELL INJECTIONSen_US
dc.typeArticleen_US
dc.relation.volume12-
dc.identifier.doi10.3934/mbe.2015.12.1237-
dc.relation.page1237-1256-
dc.relation.journalMATHEMATICAL BIOSCIENCES AND ENGINEERING-
dc.contributor.googleauthorWares, Joanna R.-
dc.contributor.googleauthorCrivelli, Joseph J.-
dc.contributor.googleauthorYun, Chae-Ok-
dc.contributor.googleauthorChoi, Il-Kyu-
dc.contributor.googleauthorGevertz, Jana L.-
dc.contributor.googleauthorKim, Peters S.-
dc.relation.code2015013430-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF ENGINEERING[S]-
dc.sector.departmentDEPARTMENT OF BIOENGINEERING-
dc.identifier.pidchaeok-
dc.identifier.researcherIDP-3698-2015-
dc.identifier.orcidhttp://orcid.org/0000-0002-9466-4531-
Appears in Collections:
COLLEGE OF ENGINEERING[S](공과대학) > BIOENGINEERING(생명공학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE